Quantcast
Last updated on April 18, 2014 at 17:24 EDT

Latest Overactive bladder Stories

How Does Your Bladder Know When To Go?
2013-02-09 07:40:44

April Flowers for redOrbit.com - Your Universe Online Millions suffer from overactive bladder or incontinence, and now help might be on the way. A new study, led by Harvard Medical School, reveals that the epithelium, a thin layer of cells lining the surface of the bladder, is able to sense how full the bladder is through the action of a family of proteins called integrins. The cells of the epithelium stretch and become thinner as the bladder fills. This activates the integrins, causing...

2013-01-25 12:25:20

WHITEHOUSE STATION, N.J., Jan. 25, 2013 /PRNewswire/ -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved OXYTROL FOR WOMEN (oxybutynin transdermal system, 3.9 mg/day), the first and only over-the-counter (OTC) treatment for overactive bladder in women. OXYTROL FOR WOMEN addresses an important unmet need for overactive bladder, or OAB, a condition that affects more than 20 million American women....

2013-01-14 16:23:15

MINNEAPOLIS, Jan. 14, 2013 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI) announced today that it will release financial results for the third quarter of fiscal 2013 ended December 31, 2012 at the market close on Thursday, January 24, 2013. The Company will host a conference call to discuss these results on Thursday, January 24, 2013 at 4:30 p.m. Eastern Time (3:30 p.m. Central Time). David Kaysen, President and Chief Executive Officer, and Medi Jiwani, Vice President, Chief Financial Officer...

2013-01-03 08:26:44

MOUNTAIN VIEW, Calif., Jan. 3, 2013 /PRNewswire/ -- TheraVida, Inc., a clinical-stage biopharmaceutical company developing novel combination drug products, announced positive results from a Phase 2 clinical trial of its lead product candidate Tolenix((TM)) (THVD-201) for the treatment of overactive bladder (OAB) and urge urinary incontinence (UUI). Tolenix((TM)) is a twice-daily (BID) proprietary combination of tolterodine, a muscarinic antagonist used to treat OAB, and pilocarpine, a...

2012-12-06 08:26:13

MINNEAPOLIS, Dec. 6, 2012 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ:UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today highlighted results of a study that compared the cost effectiveness of neuromodulation therapies for Overactive Bladder (OAB) patients over two years of treatment. The study compared percutaneous tibial nerve stimulation (PTNS) delivered via Uroplasty's Urgent(®) PC...

2012-11-27 08:27:29

MINNEAPOLIS, Nov. 27, 2012 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today announced significant new coverage decisions by private payers and Medicare. Effective October 2012, Health Net(®), one of the largest private insurance payers in California, began covering posterior tibial nerve stimulation (PTNS) for the treatment of overactive bladder...

2012-11-06 16:28:04

MINNEAPOLIS, Nov. 6, 2012 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that it will participate in two upcoming investor conferences in November - the Stephens Fall Investment Conference and the Lazard 9(th) Annual Healthcare Conference. Detailed information is provided below: What: Stephens Fall Investment...

2012-11-02 15:22:35

WASHINGTON, Nov. 2, 2012 /PRNewswire/ -- Nearly one in five women in the United States (U.S.) suffer from overactive bladder (OAB),(I, II) yet 80 percent of women with OAB never seek treatment and more than half believe that there are no effective treatments.(III) As a result, women who suffer from OAB try to manage the condition on their own through coping strategies that include pads, dark clothing, toilet mapping and avoiding social activities outside the home. Research shows that trying...

2012-10-25 04:03:17

The practitioners of Women´s Excellence in Bladder Control help women everyday find OAB treatment that is effective, safe, and with the fewest side effects possible. Lake Orion, MI (PRWEB) October 24, 2012 Medications that treat OAB are known collectively as “anticholinergics”. These medications reduce symptoms of urinary frequency, urgency, and urge incontinence but also have side effects including dry mouth, constipation, and urinary retention which can also cause...

2012-10-22 07:29:08

NORTHBROOK, Ill., Oct. 22, 2012 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas"), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), announced today that MYRBETRIQ(TM) (mirabegron) extended-release tablets, indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and urinary frequency, is now available through U.S. pharmacies. "The availability of MYRBETRIQ marks an important milestone in our ongoing...